• AVLN share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • Price change

    The price of AVLN shares has increased $2.48 since the market last closed. This is a 9.30% rise.

  • Closed at $29.15.

    The stock has remained unchanged in after-hours trading.

Key terms

About AVLN

Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). The company was founded by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar on May 27, 2011 and is headquartered in Boston, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $1.29B

    A market capitalization between $300 million and $2 billion places AVLN in the small capitalization category.

Key terms

Smart score

Latest AVLN news

Oct 02, 2026 5:45am ET Avalyn Pharma initiated with an Outperform at Raymond James by TipRanks Sep 21, 2026 9:10am ET Avalyn Pharma announces published results from Phase 1 trials of AP02 by TipRanks Aug 21, 2026 8:35am ET One new option listing and two option delistings on August 21st by TipRanks Aug 21, 2026 8:30am ET One new option listing and two option delistings on August 21st by TipRanks Aug 17, 2026 4:02am ET Avalyn Pharma price target raised to $57 from $53 at Morgan Stanley by TipRanks Aug 13, 2026 10:45am ET Jefferies Sticks to Its Buy Rating for Avalyn Pharma Inc (AVLN) by TipRanks Aug 13, 2026 8:03am ET Analysts Offer Insights on NA Companies: Avalyn Pharma Inc (AVLN) and EquipmentShare.com, Inc. (EQPT) by TipRanks
Nov 03, 2026 8:00am ET Avalyn to Present at Upcoming Investor Conferences by GlobeNewswire Sep 21, 2026 9:00am ET Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile by GlobeNewswire Sep 16, 2026 4:01pm ET Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors by GlobeNewswire Sep 08, 2026 8:00am ET Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis by GlobeNewswire Sep 08, 2026 8:00am ET Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference by GlobeNewswire Aug 24, 2026 4:01pm ET Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026 by GlobeNewswire Aug 12, 2026 8:00am ET Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights by GlobeNewswire Jun 17, 2026 8:00am ET Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis by GlobeNewswire Jun 03, 2026 7:00am ET Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights by GlobeNewswire May 27, 2026 8:00am ET Avalyn to Participate in the Jefferies Global Healthcare Conference by GlobeNewswire May 21, 2026 8:00am ET Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026 by GlobeNewswire May 05, 2026 4:01pm ET Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference by GlobeNewswire May 01, 2026 4:01pm ET Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares by GlobeNewswire Apr 29, 2026 9:00pm ET Avalyn Announces Pricing of Upsized Initial Public Offering by GlobeNewswire Apr 27, 2026 8:00am ET Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury by GlobeNewswire

AVLN Financials

1-year income & revenue

  • AVLN total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • AVLN net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • AVLN earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.

Key terms

AVLN Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

AVLN Competitors

$ Market capP/E ratio$ Price1d change52-week range
  • How competitors are chosen

    AVLN's competitors are included in the Health Technology sector and Pharmaceuticals: Major group

  • Market cap: $1.29B

    A market capitalization between $300 million and $2 billion places AVLN in the small capitalization category.

Key terms

Latest investing news